These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
463 related articles for article (PubMed ID: 26078490)
1. Myeloid-Derived Suppressor Cells and Therapeutic Strategies in Cancer. Katoh H; Watanabe M Mediators Inflamm; 2015; 2015():159269. PubMed ID: 26078490 [TBL] [Abstract][Full Text] [Related]
2. Nanoparticle Systems Modulating Myeloid-Derived Suppressor Cells for Cancer Immunotherapy. Wilkerson A; Kim J; Huang AY; Zhang M Curr Top Med Chem; 2017; 17(16):1843-1857. PubMed ID: 27875974 [TBL] [Abstract][Full Text] [Related]
3. Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment. Parker KH; Beury DW; Ostrand-Rosenberg S Adv Cancer Res; 2015; 128():95-139. PubMed ID: 26216631 [TBL] [Abstract][Full Text] [Related]
4. Phenotypes, accumulation, and functions of myeloid-derived suppressor cells and associated treatment strategies in cancer patients. Jiang J; Guo W; Liang X Hum Immunol; 2014 Nov; 75(11):1128-37. PubMed ID: 25305034 [TBL] [Abstract][Full Text] [Related]
5. Suppression of T cells by myeloid-derived suppressor cells in cancer. Chen J; Ye Y; Liu P; Yu W; Wei F; Li H; Yu J Hum Immunol; 2017 Feb; 78(2):113-119. PubMed ID: 27939507 [TBL] [Abstract][Full Text] [Related]
6. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. Yu J; Du W; Yan F; Wang Y; Li H; Cao S; Yu W; Shen C; Liu J; Ren X J Immunol; 2013 Apr; 190(7):3783-97. PubMed ID: 23440412 [TBL] [Abstract][Full Text] [Related]
7. Myeloid-derived suppressor cells: The green light for myeloma immune escape. Malek E; de Lima M; Letterio JJ; Kim BG; Finke JH; Driscoll JJ; Giralt SA Blood Rev; 2016 Sep; 30(5):341-8. PubMed ID: 27132116 [TBL] [Abstract][Full Text] [Related]
8. Myeloid derived suppressor cells and their role in tolerance induction in cancer. Fujimura T; Mahnke K; Enk AH J Dermatol Sci; 2010 Jul; 59(1):1-6. PubMed ID: 20570112 [TBL] [Abstract][Full Text] [Related]
9. Myeloid-derived suppressor cells in cancer: recent progress and prospects. Khaled YS; Ammori BJ; Elkord E Immunol Cell Biol; 2013 Sep; 91(8):493-502. PubMed ID: 23797066 [TBL] [Abstract][Full Text] [Related]
10. Myeloid-derived suppressor cells in cancer: therapeutic, predictive, and prognostic implications. Diaz-Montero CM; Finke J; Montero AJ Semin Oncol; 2014 Apr; 41(2):174-84. PubMed ID: 24787291 [TBL] [Abstract][Full Text] [Related]
11. Hampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancer. Albeituni SH; Ding C; Yan J Cancer J; 2013; 19(6):490-501. PubMed ID: 24270348 [TBL] [Abstract][Full Text] [Related]
12. Myeloid-derived suppressor cells-a new therapeutic target to overcome resistance to cancer immunotherapy. Chesney JA; Mitchell RA; Yaddanapudi K J Leukoc Biol; 2017 Sep; 102(3):727-740. PubMed ID: 28546500 [TBL] [Abstract][Full Text] [Related]
13. The immunobiology of myeloid-derived suppressor cells in cancer. Motallebnezhad M; Jadidi-Niaragh F; Qamsari ES; Bagheri S; Gharibi T; Yousefi M Tumour Biol; 2016 Feb; 37(2):1387-406. PubMed ID: 26611648 [TBL] [Abstract][Full Text] [Related]
14. Immunosuppressive myeloid-derived suppressor cells can be converted into immunogenic APCs with the help of activated NKT cells: an alternative cell-based antitumor vaccine. Ko HJ; Lee JM; Kim YJ; Kim YS; Lee KA; Kang CY J Immunol; 2009 Feb; 182(4):1818-28. PubMed ID: 19201833 [TBL] [Abstract][Full Text] [Related]
15. Functional Diversity of Myeloid-Derived Suppressor Cells: The Multitasking Hydra of Cancer. Jayakumar A; Bothwell ALM J Immunol; 2019 Sep; 203(5):1095-1103. PubMed ID: 31427398 [TBL] [Abstract][Full Text] [Related]
16. Myeloid suppressor cells in cancer and autoimmunity. Sica A; Massarotti M J Autoimmun; 2017 Dec; 85():117-125. PubMed ID: 28728794 [TBL] [Abstract][Full Text] [Related]